Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Business Wire
Prioritization of mRNA therapeutics pipeline extends cash runway into 2028ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025ARCT-032 (CF) Phase 2 expected to complete enrollment by year endARCT-810 (OTC) Phase 2 interim data expected Q2 2025Investor conference call at 4:30 p.m. ET today SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates.“We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to provide meaningful Phase 2 interim data mid-year,” said Joseph Payne, President & CEO of Arcturus Therapeutics. “We are encouraged by the clinical progress of our CF and OTC programs,
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sanofi CureVac [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Attend Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Attend Upcoming Investor ConferencesBusiness Wire
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $32.00 price target on the stock.MarketBeat
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at Citigroup Inc..MarketBeat
ARCT
Earnings
- 5/12/25 - Beat
ARCT
Sec Filings
- 6/11/25 - Form 4
- 6/11/25 - Form 4
- 6/11/25 - Form 4
- ARCT's page on the SEC website